Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Standard Biotools (LAB) EBIAT (2016 - 2026)

Standard Biotools has reported EBIAT over the past 16 years, most recently at $19.3 million for Q4 2025.

  • Quarterly EBIAT rose 170.96% to $19.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$71.9 million through Dec 2025, up 43.38% year-over-year, with the annual reading at -$74.9 million for FY2025, 17.64% up from the prior year.
  • EBIAT was $19.3 million for Q4 2025 at Standard Biotools, up from -$31.7 million in the prior quarter.
  • Over five years, EBIAT peaked at $19.3 million in Q4 2025 and troughed at -$76.3 million in Q1 2022.
  • The 5-year median for EBIAT is -$21.9 million (2024), against an average of -$27.0 million.
  • Year-over-year, EBIAT crashed 305.33% in 2022 and then surged 170.96% in 2025.
  • A 5-year view of EBIAT shows it stood at -$13.8 million in 2021, then plummeted by 50.58% to -$20.8 million in 2022, then grew by 5.13% to -$19.8 million in 2023, then tumbled by 37.4% to -$27.2 million in 2024, then soared by 170.96% to $19.3 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's EBIAT are $19.3 million (Q4 2025), -$31.7 million (Q3 2025), and -$33.5 million (Q2 2025).